571 related articles for article (PubMed ID: 21486975)
1. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS
JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
Dobson SR; McNeil S; Dionne M; Dawar M; Ogilvie G; Krajden M; Sauvageau C; Scheifele DW; Kollmann TR; Halperin SA; Langley JM; Bettinger JA; Singer J; Money D; Miller D; Naus M; Marra F; Young E
JAMA; 2013 May; 309(17):1793-802. PubMed ID: 23632723
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
Lamontagne DS; Thiem VD; Huong VM; Tang Y; Neuzil KM
J Infect Dis; 2013 Oct; 208(8):1325-34. PubMed ID: 23901077
[TBL] [Abstract][Full Text] [Related]
4. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
Iversen OE; Miranda MJ; Ulied A; Soerdal T; Lazarus E; Chokephaibulkit K; Block SL; Skrivanek A; Nur Azurah AG; Fong SM; Dvorak V; Kim KH; Cestero RM; Berkovitch M; Ceyhan M; Ellison MC; Ritter MA; Yuan SS; DiNubile MJ; Saah AJ; Luxembourg A
JAMA; 2016 Dec; 316(22):2411-2421. PubMed ID: 27893068
[TBL] [Abstract][Full Text] [Related]
6. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months.
Lazcano-Ponce E; Stanley M; Muñoz N; Torres L; Cruz-Valdez A; Salmerón J; Rojas R; Herrero R; Hernández-Ávila M
Vaccine; 2014 Feb; 32(6):725-32. PubMed ID: 24355090
[TBL] [Abstract][Full Text] [Related]
7. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.
Sharma H; Parekh S; Pujari P; Shewale S; Desai S; Bhatla N; Joshi S; Pimple S; Kawade A; Balasubramani L; Thomas A; Suri V; Lalwani S; Uday R; Kamath V; Mandal R; Rajeswar A; Peedicayil A; Poli UR; Banerjee D; Sankaranarayanan R; Basu P; Muwonge R; Gairola S; Dogar V; Rao H; Shaligram U
Lancet Oncol; 2023 Dec; 24(12):1321-1333. PubMed ID: 37949086
[TBL] [Abstract][Full Text] [Related]
9. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women.
Zimmerman RK; Nowalk MP; Lin CJ; Fox DE; Ko FS; Wettick E; Cost G; Hand L; Hayes J; Michaels M
J Womens Health (Larchmt); 2010 Aug; 19(8):1441-7. PubMed ID: 20629576
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study.
Romanowski B; Schwarz TF; Ferguson LM; Peters K; Dionne M; Schulze K; Ramjattan B; Hillemanns P; Catteau G; Dobbelaere K; Schuind A; Descamps D
Hum Vaccin; 2011 Dec; 7(12):1374-86. PubMed ID: 22048171
[TBL] [Abstract][Full Text] [Related]
12. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F
J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
LaMontagne DS; Mugisha E; Pan Y; Kumakech E; Ssemaganda A; Kemp TJ; Cover J; Pinto LA; Safaeian M
Vaccine; 2014 Oct; 32(47):6303-11. PubMed ID: 25218297
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial.
Donken R; Dobson SRM; Marty KD; Cook D; Sauvageau C; Gilca V; Dionne M; McNeil S; Krajden M; Money D; Kellner J; Scheifele DW; Kollmann T; Bettinger JA; Liu S; Singer J; Naus M; Sadarangani M; Ogilvie GS
Clin Infect Dis; 2020 Aug; 71(4):1022-1029. PubMed ID: 31617568
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.
Hernández-Ávila M; Torres-Ibarra L; Stanley M; Salmerón J; Cruz-Valdez A; Muñoz N; Herrero R; Villaseñor-Ruíz IF; Lazcano-Ponce E
Hum Vaccin Immunother; 2016; 12(1):30-8. PubMed ID: 26211489
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
Mugo N; Ansah NA; Marino D; Saah A; Garner EI
Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
[TBL] [Abstract][Full Text] [Related]
17. Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis.
D'Addario M; Redmond S; Scott P; Egli-Gany D; Riveros-Balta AX; Henao Restrepo AM; Low N
Vaccine; 2017 May; 35(22):2892-2901. PubMed ID: 28455170
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
Gilca V; Sauvageau C; Boulianne N; De Serres G; Couillard M; Krajden M; Ouakki M; Murphy D; Trevisan A; Dionne M
Hum Vaccin Immunother; 2014; 10(8):2438-45. PubMed ID: 25424952
[TBL] [Abstract][Full Text] [Related]
19. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F
Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383
[TBL] [Abstract][Full Text] [Related]
20. A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys - clinical protocol.
Zeng Y; Moscicki AB; Sahasrabuddhe VV; Garcia F; Woo H; Hsu CH; Szabo E; Dimond E; Vanzzini S; Mondragon A; Butler V; DeRose H; Chow HS
BMC Cancer; 2019 Apr; 19(1):290. PubMed ID: 30935375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
